PROMATIX


Associated tags: Consultant, Computational biology, Fisher, Fine chemical, Medical device, Medical imaging, Pharmaceutical industry, University College London, Drug combination, UCL, Research, FRSB, Therapy, Patient, Aberration, Drug resistance, Cell death, Â, Disease, Cancer

Promatix and Jasmin Fisher Lab at University College London Accelerate Hunt for Oncology Therapeutics with New Algorithms for CipherPro

Retrieved on: 
Wednesday, October 26, 2022
Consultant, Therapy, Biology, Drug discovery, Doctor of Philosophy, Cancer, Disease, Â, Cell death, Drug resistance, Aberration, Patient, FRSB, Computational biology, Research, UCL, GLOBE, Time, Drug combination, University College London, Pharmaceutical industry, Medical imaging, Medical device, Management, Fine chemical, Fisher, Algorithm

CipherPro is a proprietary suite of algorithms to mine TxPro and other databanks to support oncology drug discovery and development.

Key Points: 
  • CipherPro is a proprietary suite of algorithms to mine TxPro and other databanks to support oncology drug discovery and development.
  • The agreement via UCL Consultants means Promatixs Principal Computational Scientist, Dr Daniel Holdbrook, will work with the Fisher Lab to develop new computational executable cancer models.
  • Professor Fisher, who is on the Promatix advisory board, is internationally renowned for her vision and groundbreaking achievements in this space.
  • We are pleased to work with the Promatix team to accelerate identification of new oncology therapeutic targets and suggest new drug combination treatments.